Literature DB >> 1079205

The antigenicity of carcinoembryonic antigen in man.

J M MacSween.   

Abstract

Binding of globulins to -125I CEA was detected in 10 of 24 sera from patients with cancer, 13 of 26 sera from blood donors, and 7 of 27 supernates of tumor-cell suspensions. Binding was predominantly by IgM in 10 of 14 sera tested by radioimmunoelectrophoresis. Binding was inhibited by 6 ng unlabelled CEA in one instance only, and by adsorption with blood group A erythrocytes in three cases. Binding was not increased in dialysed precipitates formed by ammonium sulfate at pH 2.5, while there was increased binding in precipitates of complexes of CEA and heterologous anti-CEA. These results confirm that human IgM binds to CEA, and in some cases binding appears to be mediated by antibodies to blood group A. However, the binding is weak and appears to be of low affinity. This suggests that binding of CEA by immunoglobulins represents cross-reactivity by antibodies to similar antigens, of which blood group A is one example.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1079205     DOI: 10.1002/ijc.2910150210

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Circulating carcinoembryonic antigen immune complexes in sera of patients with carcinomata of the gastrointestinal tract.

Authors:  K Kapsopoulou-Dominos; F A Anderer
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

2.  An approach to the routine estimation of circulating carcinoembryonic antigen immune complexes in patients with carcinomata of the gastrointestinal tract.

Authors:  K Kapsopoulou-Dominos; F A Anderer
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

Review 3.  Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

Authors:  J Schlom; J Kantor; S Abrams; K Y Tsang; D Panicali; J M Hamilton
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  [Relapse prognosis for patients with adenocarcinoma of the gastrointestinal tract on the basis of carcinoembryonic antigen (CEA) and its circulating immune complexes (author's transl)].

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Klin Wochenschr       Date:  1980-02-01

5.  Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer.

Authors:  K A Chester; R H Begent
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

6.  CEA-containing immune complexes in sera of patients with colorectal and breast cancer--analysis of complexed immunoglobulin classes.

Authors:  C Fuchs; F Krapf; P Kern; S Hoferichter; W Jäger; J R Kalden
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 7.  Carcinoembryonic antigen: function in metastasis by human colorectal carcinoma.

Authors:  J M Jessup; P Thomas
Journal:  Cancer Metastasis Rev       Date:  1989-12       Impact factor: 9.264

Review 8.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

9.  Are circulating CEA immune complexes a prognostic marker in patients with carcinoma of the gastrointestinal tract?

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.